These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9195099)

  • 21. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
    Burman WJ; Reves RR
    Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
    [No Abstract]   [Full Text] [Related]  

  • 22. Side effects of antituberculosis drugs.
    Mohan A; Sharma SK
    Am J Respir Crit Care Med; 2004 Apr; 169(7):882-3. PubMed ID: 15044223
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinically apparent liver damage during brief tuberculosis therapy].
    Estay S; Armas Merino R; Vega C; Soto JR
    Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Can Commun Dis Rep; 2001 Jul; 27(13):114-6. PubMed ID: 11443837
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
    Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
    Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Medication-induced hepatic lesions in patients with pulmonary tuberculosis].
    Gned'ko NI
    Voen Med Zh; 2002 May; 323(5):56-8. PubMed ID: 12073843
    [No Abstract]   [Full Text] [Related]  

  • 30. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
    Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
    Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On the problem of chronic liver damage following drug therapy of tuberculosis].
    Petera V; Klapálek D; Paichl P; Pecený A
    Dtsch Z Verdau Stoffwechselkr; 1965 Oct; 25(4):250-2. PubMed ID: 5888913
    [No Abstract]   [Full Text] [Related]  

  • 32. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 33. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
    ;
    MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(31):735-9. PubMed ID: 12904741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver and pancreatic injury induced by antituberculous therapy.
    Markov M; Patel K; Raeesy A; Bant A; Van Thiel DH; Nadir A
    Dig Dis Sci; 2007 Nov; 52(11):3275-81. PubMed ID: 17909976
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of pyrazinamide on the liver of tuberculosis patients. Electron microscopic study].
    Pilheu JA; de Salvo MC; Koch OR; Arias RF
    Bull Int Union Tuberc; 1984 Sep; 59(3):145-7. PubMed ID: 6518323
    [No Abstract]   [Full Text] [Related]  

  • 36. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.
    Lou HX; Shullo MA; McKaveney TP
    Pharmacotherapy; 2002 Jun; 22(6):701-4. PubMed ID: 12066961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fulminant hepatitis induced by pyrazinamide].
    Roden S; Lagneau M; Homasson JP
    Rev Pneumol Clin; 1990; 46(1):43. PubMed ID: 2371480
    [No Abstract]   [Full Text] [Related]  

  • 38. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Centrilobular liver necrosis following antimycobacterial treatment].
    Beckert W
    Z Erkr Atmungsorgane Folia Bronchol; 1971 Aug; 135(1):11-7. PubMed ID: 5209484
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.